Cobimetinib

Evidence Level: L5

Predicted Indications: 9

Cobimetinib

Pharmacist Assessment Report

Cobimetinib: From Metastatic Melanoma to Amyotrophic Lateral Sclerosis

One-Sentence Summary

Cobimetinib is a MEK1/2 inhibitor originally used to treat metastatic melanoma. The TxGNN model predicts it may be effective for amyotrophic lateral sclerosis (ALS) with a very high score, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction is based on computational modelling alone.

Quick Overview

Item	Content
Original Indication	Metastatic melanoma (the Australian licence entry does not list an approved indication text)
Predicted New Indication	Amyotrophic lateral sclerosis
TxGNN Prediction Score	0.9973
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Cobimetinib is known to be a MEK1/2 inhibitor, and its efficacy in BRAF-mutant metastatic melanoma (in combination with a BRAF inhibitor) is established. That role rests on blocking the MAPK/ERK signalling pathway.

A hypothetical link to ALS exists. In preclinical ALS models, MAPK/ERK pathway activation has been implicated in neuroinflammation and motor neuron stress. Blocking this pathway could, in theory, reduce those processes.

This link is speculative. The TxGNN score is high, but it is a computational prediction only, and no trials or publications were found. Cobimetinib’s penetration into the central nervous system is also limited (it is a P-glycoprotein substrate), which weakens the translational plausibility.

Other high-scoring predictions follow the same pattern. Most are ALS variants or related motor neuron disorders (for example ALS susceptibility, ALS type 22, Mills syndrome, lower motor neuron syndrome and monomelic amyotrophy). These overlap with the main ALS prediction and should not be counted as independent evidence. The remaining predictions are rare developmental or skeletal conditions with no established mechanistic link.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 11074W	Cotellic	Tablet 20 mg (oral)	Not listed in the data compiled for this report

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (MEK inhibitor)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the PI (the prediction rationale notes dermatologic, ocular, hepatic, cardiac and bleeding toxicities)
Handling Protection	Please refer to the PI and local handling policies

Safety Considerations

Drug Interactions: The interaction screen returned 100 interactions in total. The main ones are listed below (a subset was provided in the compiled data).
- Major: aprepitant, dexamethasone, clarithromycin, cobicistat, samarium (153Sm) lexidronam
- Moderate: cimetidine, clotrimazole, miconazole, eliglustat, metreleptin, naltrexone, rolapitant, troglitazone, deferasirox, palifermin, strontium chloride Sr-89, fostamatinib, ticagrelor, quinine, ivacaftor
Disease-specific concern: Cobimetinib is associated with ocular toxicity (for example serous retinopathy). This is relevant for the retinal degeneration syndrome (trichomegaly-retina pigmentary degeneration-dwarfism syndrome) among the predictions.

Warnings and contraindications from the label were not available. Please refer to the TGA-approved Product Information (PI) for these.

Conclusion and Next Steps

Decision: Hold

Rationale: The predictions rest entirely on a computational model. There are no clinical trials or publications for any of the ten predicted indications (evidence level L5), and the mechanistic rationale for ALS is hypothetical and limited by poor CNS penetration. Cobimetinib’s toxicity profile is also substantial for diseases that are slowly progressive or self-limiting.

To proceed, the following is needed:

Mechanism of action data to support a mechanistic-link analysis
TGA Product Information warnings and contraindications for safety screening
Preclinical evidence in ALS models, including CNS exposure data
A literature and trial registry search (including ANZCTR) for MEK inhibitors in motor neuron disease
A risk-benefit assessment given the drug’s toxicity profile in the target populations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.